MotherToBaby

Medications and More during pregnancy and breastfeeding

Search

866.626.6847

Azelastine (Astelin®, Optivar®)

Selected References:

  • Ito S, et al. 1993. Prospective follow-up of adverse reactions in breast-fed infants exposed to maternal medication. Am J Obstet Gynecol. 168:1393-9.
  • Messinis IE, et al. 1985. Histamine H1 receptor participation in the control of prolactin secretion in postpartum. J Endocrinol Invest. 8:143-6.
  • Perrigo New York Inc. 2021. Azelastine HCl Nasal Solution prescribing information. Available at https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ccb6046c-3c10-42c6-aa22-23192c21a5fa
  • Pontiroli AE, et al. 1981. The effect of histamine and H1 and H2 receptors on prolactin and luteinizing hormone release in humans: sex differences and the role of stress. J Clin Endocrinol Metab. 52:924-8.
  • Suzuki Y, et al. 1981. Teratology and reproduction studies of azelastine, a novel antiallergic agent, in rats and rabbits. Arzneim-Forsch. 31:1225-30.
  • Tatsumi K, et al. 1980. Studies of metabolic fate of a new antiallergic agent, azelastine. Jpn J Pharmacol. 30:37-48.

This website is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $6,000,000 with zero percentage financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, HRSA, HHS, or the U.S. Government.